Excellence

AVXL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead the Anavex Class Action Lawsuit

Retrieved on: 
Mittwoch, März 13, 2024
Central nervous system, Patient, SAN, News, Rett, Rett syndrome, Complaint, Excellence, Tobacco

), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.

AVXL STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights and Remedies Against Anavex Life Sciences Corporation

Retrieved on: 
Sonntag, März 31, 2024
Class Action Lawsuit, Professional Services, Legal, Rett, Excellence, Central nervous system, Patient, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Anavex sponsored the “Excellence” Phase II/Phase III study to investigate blarcamesine as a treatment for pediatric Rett syndrome patients.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL)

Retrieved on: 
Mittwoch, März 27, 2024
Class Action Lawsuit, Professional Services, Legal, GPM, News, Avatar, Suite, Trial of the century, Excellence, Court

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL ) securities between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL ) securities between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On January 2, 2024, Anavex announced results from a Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome, reporting that the “co-primary endpoint .
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Anavex Life Sciences Corp. (AVXL)

Retrieved on: 
Dienstag, März 26, 2024
Class Action Lawsuit, Professional Services, Legal, Law, Telephone, News, Avatar, Suite, Trial of the century, Excellence, Court, Cryptocurrency

Investors suffering losses on their Anavex investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at (215) 638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Anavex investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at (215) 638-4847 or by email to [email protected] .
  • On January 2, 2024, Anavex announced results from a Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome, reporting that the “co-primary endpoint .
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corp. (AVXL) Investors

Retrieved on: 
Montag, März 25, 2024
Class Action Lawsuit, Professional Services, Legal, Law, News, Avatar, Suite, Trial of the century, Excellence, Court, Person

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL ) securities between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL ) securities between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).
  • Anavex investors have until May 13, 2024 to file a lead plaintiff motion.
  • If you are a shareholder who suffered a loss, click here to participate.
  • On January 2, 2024, Anavex announced results from a Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome, reporting that the “co-primary endpoint .

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Donnerstag, März 21, 2024
Class Action Lawsuit, Professional Services, Legal, Central nervous system, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Fraud, Excellence, FDA, Central nervous system disease, Court, Person, Pharmaceutical industry

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) and certain of its officers.

Key Points: 
  • Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) and certain of its officers.
  • Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corp. (AVXL) Investors

Retrieved on: 
Donnerstag, März 21, 2024
Class Action Lawsuit, Professional Services, Legal, Law, Telephone, News, Avatar, Suite, Trial of the century, Excellence

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL ) securities between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).

Key Points: 
  • Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL ) securities between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).
  • Anavex investors have until May 13, 2024 to file a lead plaintiff motion.
  • Investors suffering losses on their Anavex investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • On January 2, 2024, Anavex announced results from a Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome, reporting that the “co-primary endpoint .

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corp. (AVXL) Investors

Retrieved on: 
Donnerstag, März 21, 2024
Class Action Lawsuit, Professional Services, Legal, GPM, News, Avatar, Suite, Trial of the century, Excellence, Court

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL ) securities between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL ) securities between February 1, 2022 and January 1, 2024, inclusive (the “Class Period”).
  • Anavex investors have until May 13, 2024 to file a lead plaintiff motion.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On January 2, 2024, Anavex announced results from a Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome, reporting that the “co-primary endpoint .

Anavex Life Sciences Corporation Stockholder Alert: Robbins LLP Reminds Investors of AVXL Class Action

Retrieved on: 
Montag, März 18, 2024
Class Action Lawsuit, Professional Services, Legal, Rett, Excellence, Central nervous system, Patient, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • Anavex sponsored the “Excellence” Phase II/Phase III study to investigate blarcamesine as a treatment for pediatric Rett syndrome patients.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.

AVXL INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Dienstag, März 19, 2024
Class Action Lawsuit, Professional Services, Legal, Central nervous system, Patient, News, Rett, Rett syndrome, Complaint, Excellence, Tobacco

), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Anavex class action lawsuit charges Anavex and an Anavex executive with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.